SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Are sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) associated with reduced cardiovascular risk in patients with type 2 diabetes and concomitant nonalcoholic fatty liver disease (NAFLD)?